Experimental cancer drug trial halted early – what we know

NCT ID NCT05578092

Terminated Disease control Sponsor: Mirati Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors that have certain gene mutations (KRAS-MAPK pathway). The main goals were to check safety and how the drug moves through the body. The trial was terminated early, so it did not reach later phases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRTX0902 (SOS1 inhibitor) and adagrasib (KRAS G12C inhibitor)
What this could lead to: If successful, this could point toward a new treatment option for certain advanced cancers with specific gene mutations.
What could go wrong: This was a very early (Phase 1) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer colorectal neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR COLO-RECTAL CANCER NON-SMALL CELL LUNG CANCER SOLID TUMOR

Contacts and locations

Locations

Local Institution - 001-101

Nashville, Tennessee, 37203, United States
Local Institution - 001-102

Nashville, Tennessee, 37203, United States
Local Institution - 001-103

Baltimore, Maryland, 21287, United States
Local Institution - 001-104

Fairfax, Virginia, 22031, United States
Local Institution - 001-105

Seattle, Washington, 98109, United States
Local Institution - 001-106

Cincinnati, Ohio, 45219-2364, United States
Local Institution - 001-107

Houston, Texas, 77030, United States
Local Institution - 001-108

New Haven, Connecticut, 06520, United States
Local Institution - 001-109

Portland, Oregon, 97239-3011, United States
Local Institution - 001-110

Rochester, Minnesota, 55905-0001, United States
Local Institution - 001-111

Orlando, Florida, 32827-7400, United States
Local Institution - 001-112

Dallas, Texas, 75246-2003, United States
Local Institution - 001-114

Rio Piedras, 00935, Puerto Rico
Local Institution - 001-115

Hackensack, New Jersey, 07601-2191, United States
Local Institution - 001-116

Pittsburgh, Pennsylvania, 15232, United States
Local Institution - 001-119

Newark, Delaware, 19713-2055, United States
Local Institution - 001-122

Fort Worth, Texas, 76104-2154, United States
Local Institution - 001-123

Tyler, Texas, 75708-3154, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.